CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting

Key Terms

randomized controlled clinical trial medical

A randomized controlled clinical trial is a medical study where participants are randomly assigned to two or more groups—typically one receiving the treatment under test and another receiving a placebo or standard care—to objectively measure whether the treatment works and is safe. For investors, these trials are the gold standard for proving a drug or device’s effectiveness, because their clear, unbiased results strongly influence regulatory approval, market adoption, and the commercial value of healthcare companies.

pneumoperitoneum medical

Presence of air or gas inside the peritoneal cavity, the space that normally surrounds abdominal organs; it can result from surgical procedures that intentionally introduce gas, or from an unintended hole in the digestive tract that lets air escape. For investors, pneumoperitoneum matters because it is a clinical finding tied to surgical techniques, device performance, complication rates and trial safety reporting—factors that can affect healthcare costs, regulatory assessments and market perceptions of medical products or treatments.

nociceptive medical

Nociceptive describes pain that comes from actual or threatened physical damage and the body’s normal pain-sensing system detecting that damage — like the sharp sensation when you cut a finger or the ache after a sprain. For investors, distinguishing nociceptive pain from other types (for example nerve-related pain) matters because it determines which drugs or devices are likely to work, how clinical trials are designed, and the size and regulatory path of potential markets.

insufflator medical

A medical insufflator is a device that pumps and regulates gas—commonly carbon dioxide—into a body cavity during minimally invasive surgery to create and maintain a working space, controlling pressure and flow like an air pump inflating a balloon. It matters to investors because insufflators are part of the surgical device market: their sales, compatible consumables, regulatory clearances, and role in procedure adoption affect medical-device company revenues and hospital purchasing patterns.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Professor Nikhil Vasdev to Present Results of a Recently Published Clinical Trial Featuring AirSeal^® technology

LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL.

During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdominal insufflators, CONMED’s AirSeal^® Insufflation System and Stryker’s PneumoClear Insufflator.

TITLE: Utilising intra-operative artificial intelligence to investigate the difference in nociceptive stimulus between 2 different abdominal insufflators during a Robotic Prostatectomy (RALP Clinical Trial)

DATE: Friday, July 24

TIME: 8:02 AM ET

LOCATION: 314

The trial included 40 patients with localized prostate cancer who underwent a robotic prostatectomy, with either AirSeal or PneumoClear used for the management of low-pressure pneumoperitoneum (8 mmHg). Differences in the levels of significant intra-operative nociception between the two insufflators were recorded using an artificial intelligence device. The AirSeal arm of the trial had fewer significant nociceptive events per recorded hour than the PneumoClear arm (20.7 vs. 33.5, p = 0.041). Additionally, shorter procedure times (p = 0.045), console times (p = 0.045), and blood loss (p < 0.001) were seen in the AirSeal arm. The results of the trial were published in the open access journal, JUI Compass, in May, 2026 and are available via the following link: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.70226

In connection with its participation, CONMED will host a session that explores how low-pressure insufflation is redefining intraoperative performance to support surgical efficiency and enable enhanced patient recovery. The session will feature Amit Taggar, MD, FACS, FAMBS, FICS, Gabe Mena, MD FASA, Philip Woodworth, MD, FACS, and Rahila Essani, MD, FACS, FACRS.

TITLE: Why Stability at Low Pressure in Robotic Surgery Matters Intraoperatively and for Patients

DATE: Friday, July 24

TIME: 12:30 PM ET

LOCATION: Diplomat Room 4

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260720880337/en/

CONMED Corporation
Dalton Henry
Investor Relations Analyst
IR@conmed.com

Source: CONMED Corporation